Good morning, everyone, and how are you today? The middle of the week is here which, as you know, requires endurance, temerity and inspiration. We are confident, though, that you will persevere. And what better way to get started than to quaffe a cup of stimulation? We are back to Wild Mountain Blueberry and, whatever your preference, invite you to join us. We have a busy few hours ahead, of course, so here are some items of interest. Hope your day goes well and do stay in touch...
Abbott Hepatitis C Treatment Yields Impressive Study Results (Reuters)
Carl Icahn Says Amylin Should Pursue A Sale (Bloomberg News)
Sleeping Pills Pose Added Risk For Obese Patients (AmMed News)
Merck Hires Randy Jackson As Diabetes Spokesman (Drug Store News)
FDA Says Astellas Overactive Bladder Drug Raises Risks (Bloomberg News)
Glaxo Says Data Supports Filing For New Diabetes Drug (Reuters)
Express Scripts Faces Hearing On Suit To Block Medco Deal (Bloomberg News)
Pfizer Launches Agency Review (AdAge)
EDITOR'S NOTE: Please check this post for updates throughout the morning
morning coffee pic thx to chichacha on flickr